Current Report Filing (8-k)
November 19 2018 - 3:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 19, 2018
Nexeon Medsystems Inc
(Exact name of registrant as specified in
its charter)
Nevada
|
|
000-55655
|
|
81-0756622
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
1910 Pacific
Avenue, Suite 20000
Dallas, Texas 75201
(Address of principal executive offices)
(zip code)
844-919-9990
|
(Registrant’s telephone number, including area code)
|
|
Not applicable
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM
2.02 Results of Operations and Financial Condition
On November 19, 2018, Nexeon Medsystems Inc issued a press release
announcing its financial results for the third quarter ended September 30, 2018. The full text of the press release is furnished
herewith as Exhibit 99.1.
The information disclosed under this Item 2.02, including
Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other
document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
ITEM 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The exhibits listed in the following Exhibit Index are filed
as part of this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
NEXEON MEDSYSTEMS INC
|
|
|
Dated: November 19, 2018
|
/s/
William Rosellini
|
|
William Rosellini
|
|
Chairman and Chief Executive Officer
|
Nexeon Medsystems (CE) (USOTC:NXNN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nexeon Medsystems (CE) (USOTC:NXNN)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Nexeon Medsystems Inc (CE) (OTCMarkets): 0 recent articles
More Nexeon Medsystems Inc News Articles